Senate Tax ‘Avoidance’ Hearing Presents PR Headache But Policy Change Is Distant Threat
Executive Summary
Rather than entertaining revisions to the Trump tax cuts, Republicans on the Finance Committee instead challenged the Biden Administration's agreement with the Organization for Economic Co-operation and Development relating to a global minimum tax on multinational corporations.
You may also be interested in...
Under The Shadow Of Drug Price Reform, US Tax Policies Still Challenge Pharma
Congress is considering legislation that would reverse some of the Trump administration's friendly corporate tax policies, presenting another challenge to the biopharmaceutical industry.
Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds
New study updates past commission analyses and highlights the significant margin between Medicare payments for drugs and the prices paid by 340B-eligible providers.
Xtandi Pricing and Patents: Alternatives To March-In Urged To Lower Medicare, Medicaid Costs
The timing of the request, with Xtandi’s loss of exclusivity on the horizon, could be explained by the concern that a change in the US presidential administration in 2025 may limit the prospects for near-term relief.